Akebia Therapeutics (AKBA) Gross Profit (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Gross Profit data on file, last reported at $41.3 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $41.3 million, down 17.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $188.3 million (up 90.8% YoY), and the FY2025 annual result was $196.7 million, up 102.81% from the prior year.
• Gross Profit declined to $41.3 million in Q1 2026 per AKBA's latest filing, from $45.1 million in the prior quarter.
• Over five years, Gross Profit peaked at $68.2 million in Q4 2022 and troughed at -$900000.0 in Q4 2024.
• A 5-year average of $35.0 million and a median of $33.0 million in 2023 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2024 and 2025: Gross Profit slumped 102.4% in 2024, then jumped 5109.67% in 2025.
• A 5-year view of Gross Profit shows it stood at $68.2 million in 2022, then slumped by 44.99% to $37.5 million in 2023, then tumbled by 102.4% to -$900000.0 in 2024, then jumped by 5109.67% to $45.1 million in 2025, then fell by 8.5% to $41.3 million in 2026.
• Business Quant data shows AKBA's Gross Profit at $41.3 million in Q1 2026, $45.1 million in Q4 2025, and $49.4 million in Q3 2025.